- Programs & Services
- Cost Management
- Specialty Management
- Care Management
- Member Engagement
- Health Plan Client Engagement
Additional multiple chimeric antigen receptor (CAR) T-cell therapy approvals are expected in late 2021 as part of the gene therapy drug pipeline. In addition, therapies could be approved for hemophilia A, hemophilia B and many different cancers including bladder cancer and melanoma.
In our periodic gene therapy pipeline update report, we share information about treatments that the U.S. Food and Drug Administration (FDA) may review and approve.
Treatments in the drug pipeline change based on the success — or lack thereof — of clinical trials and other important data. We will continue to share updates to the gene therapy pipeline periodically.